/ Unknown statusPhase 1/2IIT A phase 1/2 study investigating the pharmacokinetics, safety and efficacy of a highly concentrated buccal formulation of apomorphine (APORON®) in subjects with Parkinson's Disease - Buccal apomorphine (APORON) administration
100 Clinical Results associated with Criceto IKM B.V.
0 Patents (Medical) associated with Criceto IKM B.V.
100 Deals associated with Criceto IKM B.V.
100 Translational Medicine associated with Criceto IKM B.V.